GILD Gilead Sciences (GILD) Insider Trading, Ownership & Congress Trades
Pharma & Biotech · Biological products, (no diagnostic substances) · CIK 0000882095
Congress · 2Form 144 · 9
Insider buyers, 180 days
0
Funds added, last quarter
1,119
13F, latest reported quarter
Conversions, 180 days
22
Codes C/M, not in net · $4.8M priced
What the filings say about GILD
Insiders, 180 days
-$25.3M net sold
5 sellers · 48% of sales under a 10b5-1 plan
Congress, 1 year
2 bought · 0 sold
Latest: purchase, 2026-05-06
Planned sales (Form 144), 90 days
$16.7M
9 notices
Gilead Sciences insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
Over the last 180 days, GILEAD SCIENCES, INC. insiders sold a net $25.3M of stock across 151 Form 4 purchases and sales, with no insider buying. Source: SEC Form 4 filings, as of 2026-10-28.
Insider
Filed
Shares
Value
Since filing
Context
- 39 earlier Form 4 trades (code P or S) here by this insider (39 sales), the last on Sep 15, 2026.
- The trade is 2.6% of the 113,684 shares held after it.
- 2 other insiders sold within 30 days.
- 1,119 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Comm & Corp Aff Officer Mercier Johanna sold about $468.7K of GILD under a 10b5-1 plan on Oct 15, 2026; 2 other insiders sold within 30 days and 1,119 funds added in the latest 13F quarter.Context
- 31 earlier Form 4 trades (code P or S) here by this insider (31 sales), the last on Sep 15, 2026.
- The trade is 1.9% of the 161,096 shares held after it.
- 2 other insiders sold within 30 days.
- 1,119 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Financial Officer Dickinson Andrew D sold about $468.7K of GILD under a 10b5-1 plan on Oct 15, 2026; 2 other insiders sold within 30 days and 1,119 funds added in the latest 13F quarter.Context
- 35 earlier Form 4 trades (code P or S) here by this insider (35 sales), the last on Sep 1, 2026.
- The trade is 2.1% of the 569,683 shares held after it.
- 2 other insiders sold within 30 days.
- 1,119 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chairman & CEO O'Day Daniel Patrick sold about $1.8M of GILD under a 10b5-1 plan on Oct 1, 2026; 2 other insiders sold within 30 days and 1,119 funds added in the latest 13F quarter.Context
- 35 earlier Form 4 trades (code P or S) here by this insider (35 sales), the last on Sep 1, 2026.
- The trade is 0.5% of the 566,683 shares held after it.
- 2 other insiders sold within 30 days.
- 1,119 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chairman & CEO O'Day Daniel Patrick sold about $445.9K of GILD under a 10b5-1 plan on Oct 1, 2026; 2 other insiders sold within 30 days and 1,119 funds added in the latest 13F quarter.Context
- 36 earlier Form 4 trades (code P or S) here by this insider (36 sales), the last on Aug 17, 2026.
- The trade is 1.4% of the 118,084 shares held after it.
- 4 other insiders sold within 30 days.
- 1,119 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Comm & Corp Aff Officer Mercier Johanna sold about $229.9K of GILD under a 10b5-1 plan on Sep 15, 2026; 4 other insiders sold within 30 days and 1,119 funds added in the latest 13F quarter.151 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
net -$25.3M over 180 days
-$15.9M over 90 days
below 90% of Pharma & Biotech
Congress
2 members bought in the last year
more than 76% of Pharma & Biotech
Funds
1,119 funds bought in last quarter
more than 99% of Pharma & Biotech
Revenue
+2.4% year over year
more than 50% of Pharma & Biotech
Margin
28.9% net margin
more than 90% of Pharma & Biotech
Buybacks
$774.0M repurchased, FY to 2026-06-30
more than 91% of Pharma & Biotech
Short interest
1.6% of the float short (float per yahoo 2026-10-27) · 3.7 days to cover · settled 2026-10-15
below 68% of Pharma & Biotech
The situation: each line is one rule over one dataset
2 clinical trials were terminated, suspended or withdrawn in the last 90 days.
What changed in the last 30 days
Oct 16Chief Financial Officer Dickinson Andrew D sold $468.7K under a 10b5-1 plan (Oct 15)
Why it matters
A 10b5-1 plan schedules trades months ahead, so this says little about what the insider thinks today.
Oct 16Chief Comm & Corp Aff Officer Mercier Johanna sold $468.7K under a 10b5-1 plan (Oct 15)
Why it matters
A 10b5-1 plan schedules trades months ahead, so this says little about what the insider thinks today.
Oct 15Officer ANDREW DICKINSON filed to sell $468.7K by Oct 15 (Form 144)
Why it matters
A Form 144 is a notice of intent to sell; the sale may not happen, and it says nothing about the price.
Oct 15Officer JOHANNA MERCIER filed to sell $468.7K by Oct 15 (Form 144)
Why it matters
A Form 144 is a notice of intent to sell; the sale may not happen, and it says nothing about the price.
Oct 2Chairman & CEO O'Day Daniel Patrick sold $2.2M under a 10b5-1 plan (Oct 1)
Why it matters
A 10b5-1 plan schedules trades months ahead, so this says little about what the insider thinks today.
Watch GILD
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
+33.9%12M
Insider sellForm 144 (planned sale)
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns GILD: institutional holders (13F)
13F holdings, latest reported quarter
121,844,108 sh
$15.4B
81,091,734 sh
$10.2B
66,870,816 sh
$8.4B
61,216,552 sh
$7.7B
40,988,975 sh
$5.2B
Congress trades in GILD
STOCK Act disclosures, US House only, filed up to 45 days after the trade
Bought 2026-05-06 · disclosed 44 days later
$1,001 - $15,000
Bought 2026-01-27 · disclosed 30 days later
$1,001 - $15,000
Sold 2025-09-23 · disclosed 17 days later
$1,001 - $15,000
Bought 2025-06-06 · disclosed 12 days later
$1,001 - $15,000
Sold 2025-05-14 · disclosed 28 days later
$1,001 - $15,000
Activist and 5% holders (13D/13G)
No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.
GILD planned insider sales (Form 144)
Notice of intent to sell, filed before any sale
ANDREW DICKINSON
Filed 2026-10-15
$468.7K
JOHANNA MERCIER
Filed 2026-10-15
$468.7K
ANDREW DICKINSON
Filed 2026-09-15
$435.9K
JOHANNA MERCIER
Filed 2026-09-15
$432.6K
ANTHONY WELTERS
Filed 2026-08-26
$2.7M
GILD mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
VanEck Biotech ETF
$50.6M position · as of 2026-06-30
12.8%
Invesco Nasdaq Biotechnology ETF
$5.0M position · as of 2026-05-31
7.4%
iShares Biotechnology ETF
$621.8M position · as of 2026-06-30
6.8%
Fidelity Advisor Biotechnology Fund
$125.5M position · as of 2026-07-31
5.7%
AlphaCentric Life Sciences and Healthcare Fund
$2.6M position · as of 2026-06-30
5.5%
Harbor Health Care ETF
$2.1M position · as of 2026-07-31
5.1%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Clinical pipeline
144 registered trials, 67 still running (ClinicalTrials.gov).
A status change is dated here weeks before the press release.
34
Phase 1
13 active
43
Phase 2
22 active
39
Phase 3
20 active
3
Phase 4
1 active
8
Not applicable
1 active
17
Multi-phase
10 active
What changed recently
Study of Seladelpar and Cilofexor in Participants With Primary Biliary Cholangitis
2026-10-28 · Completion moved 2028-06 → 2028-12
Phase 2
Study of Seladelpar and Cilofexor in Participants With Primary Biliary Cholangitis
2026-10-28 · Not Yet Recruiting → Recruiting
Phase 2
Substudy-01: A Study of Long-Acting HIV-1 Treatments Taken by Mouth in People With HIV-1
2026-10-24 · Not Yet Recruiting → Recruiting
Phase 2
Study of GS-4571 in Healthy Participants, Nondiabetic Obese Participants, and Nonobese P
2026-10-07 · Completion moved 2026-11 → 2027-02
Phase 1
Study of Bictegravir/Lenacapavir in Children and Adolescents With HIV-1
2026-09-30 · Completion moved 2026-11 → 2030-07
PHASE2,PHASE3
Study of Bulevirtide in Participants With Chronic Hepatitis D Infection
2026-09-19 · Active Not Recruiting → Terminated · Sponsor decision, no safety concerns.
,
Matched by sponsor name. Trials run under a subsidiary's
own name are not included.
Corporate PAC
The company's PAC: committee totals only, never individual donors (FEC).
Gilead Sciences Inc Healthcare Policy Pac
Cycle 2026 · $733K spent
$585.6K
Federal Election Commission, matched by the PAC's connected organisation
Executive pay vs shareholder return · Mr. O’Day
CEO pay, headline and as actually paid, against the company's
return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2025
$28.4M
$63.3M
$9.2M
+155%
+25%
2024
$23.7M
$44.8M
$7.7M
+87%
-7%
2023
$22.6M
$15.5M
$7.6M
+57%
-6%
2022
$21.6M
$55.0M
$7.9M
+61%
-10%
2021
$19.2M
$31.5M
$6.3M
+30%
+0%
Tagged by the company under SEC Item 402(v). Returns are
cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders have filed to sell, before selling.
The record shows a net $25.3M sold by insiders over 180 days, 1,119 funds added last quarter, 2 House member(s) bought in 12 months, disclosed weeks after the trade, $16.7M in planned Form 144 sales. Each figure is a federal filing, dated the day it went public.
GILD financials
Revenue growth
+2.4%
XBRL, annual
Net margin
28.9%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$30.5B
four quarters, 2025-07-01 to 2026-06-30
Revenue, TTM GILD
| FY Dec 2025 | $29.4B |
| FY Dec 2024 | $28.8B |
| FY Dec 2023 | $27.1B |
| FY Dec 2022 | $27.3B |
| FY Dec 2021 | $27.3B |
| Jun 2026 | $7.8B |
| Mar 2026 | $7.0B |
| Dec 2025 | $7.9B |
| Sep 2025 | $7.8B |
| Jun 2025 | $7.1B |
| Mar 2025 | $6.7B |
| Dec 2024 | $7.6B |
| Sep 2024 | $7.5B |
At each fiscal year end
Single quarter
Net margin, TTM
-10.6%
net income over revenue, 2025-07-01 to 2026-06-30
Net margin, TTM GILD
| FY Dec 2025 | +28.9% |
| FY Dec 2024 | +1.7% |
| FY Dec 2023 | +20.9% |
| FY Dec 2022 | +16.8% |
| FY Dec 2021 | +22.8% |
| Jun 2026 | -134.5% |
| Mar 2026 | +29.0% |
| Dec 2025 | +27.5% |
| Sep 2025 | +39.3% |
| Jun 2025 | +27.7% |
| Mar 2025 | +19.7% |
| Dec 2024 | +23.6% |
| Sep 2024 | +16.6% |
At each fiscal year end
Single quarter
Free cash flow, TTM
$12.9B
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Free cash flow, TTM GILD
| FY Dec 2025 | $9.5B |
| FY Dec 2024 | $10.3B |
| FY Dec 2023 | $7.4B |
| FY Dec 2022 | $8.3B |
| FY Dec 2021 | $10.8B |
| Jun 2026 | $3.4B |
| Mar 2026 | $2.4B |
| Dec 2025 | $3.1B |
| Sep 2025 | $4.0B |
| Jun 2025 | $720.0M |
| Mar 2025 | $1.7B |
| Dec 2024 | $2.8B |
| Sep 2024 | $4.2B |
At each fiscal year end
Single quarter
Debt to equity
2.22x
long-term 2026-06-30 plus current 2026-06-30; equity 2026-06-30
Debt to equity GILD
| FY Dec 2025 | 1.10x |
| FY Dec 2024 | 1.38x |
| FY Dec 2023 | 1.09x |
| FY Dec 2022 | 1.19x |
| FY Dec 2021 | 1.27x |
| Jun 2026 | 2.22x |
| Mar 2026 | 0.94x |
| Dec 2025 | 1.10x |
| Sep 2025 | 1.16x |
| Jun 2025 | 1.27x |
| Mar 2025 | 1.30x |
| Dec 2024 | 1.38x |
| Sep 2024 | 1.26x |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
0.52x
TTM operating cash flow over long-term 2026-06-30 plus current 2026-06-30
Cash flow to debt GILD
| FY Dec 2025 | 0.40x |
| FY Dec 2024 | 0.41x |
| FY Dec 2023 | 0.32x |
| FY Dec 2022 | 0.36x |
| FY Dec 2021 | 0.43x |
| Jun 2026 | 0.52x |
| Mar 2026 | 0.49x |
| Dec 2025 | 0.40x |
| Sep 2025 | 0.39x |
| Jun 2025 | 0.40x |
| Mar 2025 | 0.42x |
| Dec 2024 | 0.41x |
| Sep 2024 | 0.43x |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
-20.6%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on equity GILD
| FY Dec 2025 | +40.5% |
| FY Dec 2024 | +2.3% |
| FY Dec 2023 | +25.7% |
| FY Dec 2022 | +21.7% |
| FY Dec 2021 | +31.7% |
| Jun 2026 | -20.6% |
| Mar 2026 | +43.2% |
| Dec 2025 | +40.5% |
| Sep 2025 | +40.5% |
| Jun 2025 | +33.3% |
| Mar 2025 | +32.5% |
| Dec 2024 | +2.3% |
| Sep 2024 | +0.6% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
-6.2%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets GILD
| FY Dec 2025 | +14.4% |
| FY Dec 2024 | +0.8% |
| FY Dec 2023 | +9.0% |
| FY Dec 2022 | +7.0% |
| FY Dec 2021 | +9.1% |
| Jun 2026 | -6.2% |
| Mar 2026 | +16.4% |
| Dec 2025 | +14.4% |
| Sep 2025 | +14.3% |
| Jun 2025 | +11.5% |
| Mar 2025 | +10.6% |
| Dec 2024 | +0.8% |
| Sep 2024 | +0.2% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
n/a
pre-tax loss, no effective tax rate to apply
Return on invested capital GILD
| FY Dec 2025 | +21.5% |
| FY Dec 2024 | +2.7% |
| FY Dec 2023 | +14.9% |
| FY Dec 2022 | +14.0% |
| FY Dec 2021 | +18.3% |
| Jun 2026 | n/a |
| Mar 2026 | +23.4% |
| Dec 2025 | +21.5% |
| Sep 2025 | +21.7% |
| Jun 2025 | +18.3% |
| Mar 2025 | +18.9% |
| Dec 2024 | +2.7% |
| Sep 2024 | +1.4% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
-6.0%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
Return on capital employed GILD
| FY Dec 2025 | +21.3% |
| FY Dec 2024 | +3.4% |
| FY Dec 2023 | +14.8% |
| FY Dec 2022 | +13.5% |
| FY Dec 2021 | +17.5% |
| Jun 2026 | -6.0% |
| Mar 2026 | +22.8% |
| Dec 2025 | +21.3% |
| Sep 2025 | +23.6% |
| Jun 2025 | +18.4% |
| Mar 2025 | +18.8% |
| Dec 2024 | +3.4% |
| Sep 2024 | +1.8% |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
P/E, trailing GILD
| FY Dec 2025 | 18.13x |
| FY Dec 2024 | 249.65x |
| FY Dec 2023 | 18.04x |
| FY Dec 2022 | 23.52x |
| FY Dec 2021 | 14.73x |
| Jun 2026 | n/a |
| Mar 2026 | 18.99x |
| Dec 2025 | 18.13x |
| Sep 2025 | 17.21x |
| Jun 2025 | 22.09x |
| Mar 2025 | 23.59x |
| Dec 2024 | 249.65x |
| Sep 2024 | 1,048.00x |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
$217.6B
market value at close 2026-10-26 on 2026-07-31 shares, plus long-term 2026-06-30 plus current 2026-06-30, minus cash 2022-12-31
Enterprise value GILD
| FY Dec 2025 | $171.8B |
| FY Dec 2024 | $136.4B |
| FY Dec 2023 | $120.5B |
| FY Dec 2022 | $127.5B |
| FY Dec 2021 | $112.4B |
| Jun 2026 | $177.7B |
| Mar 2026 | $189.8B |
| Dec 2025 | $171.8B |
| Sep 2025 | $157.3B |
| Jun 2025 | $157.4B |
| Mar 2025 | $159.1B |
| Dec 2024 | $136.4B |
| Sep 2024 | $122.2B |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
+6.6%
TTM free cash flow over market value at close 2026-10-26
FCF yield GILD
| FY Dec 2025 | +6.2% |
| FY Dec 2024 | +9.0% |
| FY Dec 2023 | +7.4% |
| FY Dec 2022 | +7.7% |
| FY Dec 2021 | +11.9% |
| Jun 2026 | +8.3% |
| Mar 2026 | +5.9% |
| Dec 2025 | +6.2% |
| Sep 2025 | +6.7% |
| Jun 2025 | +6.8% |
| Mar 2025 | +7.1% |
| Dec 2024 | +9.0% |
| Sep 2024 | +9.0% |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
PEG, trailing GILD
| FY Dec 2025 | 0.01x |
| FY Dec 2024 | n/a |
| FY Dec 2023 | 0.78x |
| FY Dec 2022 | n/a |
| FY Dec 2021 | 0.00x |
| Jun 2026 | n/a |
| Mar 2026 | 0.35x |
| Dec 2025 | 0.01x |
| Sep 2025 | 0.00x |
| Jun 2025 | 0.04x |
| Mar 2025 | 0.02x |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2025-12 | 2024-12 | 2023-12 | 2022-12 | |
|---|---|---|---|---|
| Revenue | $29.4B | $28.8B | $27.1B | $27.3B |
| Operating income | $10.0B | $1.7B | $7.6B | $7.3B |
| Net income | $8.5B | $480.0M | $5.7B | $4.6B |
| EPS (diluted) | 6.78 | 0.38 | 4.50 | 3.64 |
| Operating cash flow | $10.0B | $10.8B | $8.0B | $9.1B |
| Cash | n/a | n/a | n/a | $5.4B |
| Long-term debt | $22.1B | $24.9B | $23.2B | $23.0B |
| Buybacks | $1.9B | $1.1B | $1.0B | $1.4B |
| Dividends paid | $4.0B | $3.9B | $3.8B | $3.7B |
SEC XBRL, fiscal years, as known on 2026-10-28
GILD Stock Sonar score 6/7 axes
Find similar shapesCompareGILD ranks highest on institutional and government (98th percentile) and profitability (76th), and lowest on insider conviction (6th), among Pharma & Biotech peers.
6 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
GILD filings, in plain words
Are Gilead Sciences insiders buying or selling GILD?
In the 180 days to 2026-10-28, Gilead Sciences insiders were net sellers, a net $25.3M across purchases and sales reported on Form 4, by 5 sellers.
Have members of Congress traded GILD?
Yes. In the year to 2026-10-28, 2 House members disclosed buying GILD and 0 House members disclosed selling it; the latest on record is a purchase by Jared Moskowitz dated 2026-05-06.
Are there planned insider sales of GILD?
Yes. 9 Form 144 notices of planned insider sales were filed in the 90 days to 2026-10-28, covering $16.7M of stock; the latest, by ANDREW DICKINSON, was filed 2026-10-15.
Read the full summary
In the 180 days to 2026-10-28, Gilead Sciences insiders were net sellers of GILD, a net $25.3M across purchases and sales reported on Form 4 by 5 sellers. 48% of the 42 insider sales were made under a Rule 10b5-1 plan; the rest were not flagged as planned. In the year to 2026-10-28, 2 members of Congress disclosed buying GILD and 0 members disclosed selling it; the latest on record is a purchase by Jared Moskowitz dated 2026-05-06. Insiders filed 9 Form 144 notices of intent to sell in the 90 days to 2026-10-28, covering $16.7M of stock. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
